Made In Victoria: A Groundbreaking Peanut Allergy Therapy
Posted: 29 January 2024 The Allan Labor Government’s investment into a local biotechnology firm will bring peanut allergy sufferers around the world one step closer to an innovative new treatment that could save lives. Minister for Economic Growth…
Research overturns thinking into potential Parkinson’s disease target
Posted: 29 January 2024 A new study has found a molecule hailed as a potential drug candidate for Parkinson’s disease is no longer an effective therapeutic option. The WEHI-led research has debunked over 10 years of research that suggested a…
Study pinpoints breast cancer ‘cells-of-origin’ in high-risk women
Posted: 29 January 2024 Scientists have pinpointed likely ‘cells-of-origin’, the source cells that can grow into breast cancer, in women carrying a faulty BRCA2 gene who are at high risk of developing the disease. The WEHI-led study also showed…
New Cellular Lab To Back Victorian Blood Cancer Research
Posted: 29 January 2024 The Allan Labor Government is celebrating the opening of a new cellular laboratory at St Vincent’s Hospital Melbourne, which deliver more local research into blood cancers than ever before. Acting Minister for Health Ingrid…
Discovery of drug candidate to potentially tackle ER-positive breast cancer
Posted: 29 January 2024 An international team of researchers, led by Pfizer in collaboration with Monash University and the Australian-based Cancer Therapeutics Cooperative Research Centre, have discovered a pre-clinical drug candidate demonstrating anti-tumour activity in Estrogen Receptor (ER)…
4DMedical partners with Philips to expand US Defence commercialisation
Posted: 25 January 2024 ASX-listed imaging technology developer 4DMedical Limited has signed a teaming agreement with Koninklijke Philips, a leading global healthcare company, to commercialise 4D Medical’s XV Technology within the US Department of Veterans Affairs. The partnership marks a…
DEP cabazitaxel data presentation at ASCO GI cancer meeting
Posted: 22 January 2024 Starpharma today announces the presentation of the positive results from its Phase 2 clinical trial of DEP® cabazitaxel at the American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium[1], which is being held from…
FDA clearance of Amplia’s IND for pancreatic cancer trial in US
Posted: 19 January 2024 Amplia Therapeutics Limited is pleased to announce that the US FDA have cleared Amplia’s IND application for a trial of Amplia’s best-in-class focal adhesion kinase (FAK) inhibitor narmafotinib in pancreatic cancer. The proposal trial…
Amplia Reports First Patient Dosing in Phase 2A Accent Trial
Posted: 19 January 2024 Amplia Therapeutics Limited is pleased to announce that the first patient in the Phase 2a portion of the ACCENT trial has begun dosing. The ACCENT trial is examining the combination of Amplia’s best-in-class FAK…
A $268 million investment to support innovative research projects
Posted: 22 December 2023 With a focus on innovation and creativity, NHMRC’s Ideas Grant scheme enables researchers at all career stages to work together to address specific research questions to advance within their field for the improvement of…
i-body®-ENABLED BREAKTHROUGH IN MALARIA TREATMENT
Posted: 22 December 2023 In collaboration with La Trobe University, AdAlta has discovered an i-body® believed to be the first ever antibody-like molecule capable of high potency inhibition of malaria parasite invasion of red blood cells and liver…
$1.7 million funding boosts skin disease research at the Doherty Institute
Posted: 22 December 2023 University of Melbourne’s Professor Laura Mackay, Laboratory Head and Immunology Theme Leader at the Doherty Institute, and the University of Melbourne’s Associate Professor Sarah Dunstan, Principal Research Fellow in Infectious Diseases and a Lead of the…
